Yaobin Lin

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.

Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.

Journal: Journal for immunotherapy of cancer

Published: June 24, 2026

Surgical strategy after neoadjuvant immunochemotherapy for central-type NSCLC: restaging-guided versus pre-treatment-guided decision-making.

Surgical strategy after neoadjuvant immunochemotherapy for central-type NSCLC: restaging-guided versus pre-treatment-guided decision-making.

Journal: Translational lung cancer research

Published: March 01, 2026

Progress in Immunotherapy for Pulmonary Lymphoepithelioma Carcinoma

Progress in Immunotherapy for Pulmonary Lymphoepithelioma Carcinoma

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: January 07, 2026

A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.

A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.

Journal: Journal of translational internal medicine

Published: December 24, 2025

Efficacy of Neoadjuvant Immunochemotherapy in Pulmonary Lymphoepithelioma Carcinoma Compared With Lung Squamous Cell Carcinoma and Adenocarcinoma: A Retrospective Cohort Study.

Efficacy of Neoadjuvant Immunochemotherapy in Pulmonary Lymphoepithelioma Carcinoma Compared With Lung Squamous Cell Carcinoma and Adenocarcinoma: A Retrospective Cohort Study.

Journal: Cancer medicine

Published: October 09, 2025

Baseline multi-omics signatures could predict therapeutic response to neoadjuvant anti-PD-1 immunochemotherapy in non-small-cell lung cancer.

Baseline multi-omics signatures could predict therapeutic response to neoadjuvant anti-PD-1 immunochemotherapy in non-small-cell lung cancer.

Journal: Clinical and translational medicine

Published: August 11, 2025

Safety and necessity of omitting mediastinal lymph node dissection in cN0/N1 non-small cell lung cancer after neoadjuvant immunotherapy.

Safety and necessity of omitting mediastinal lymph node dissection in cN0/N1 non-small cell lung cancer after neoadjuvant immunotherapy.

Journal: Frontiers in immunology

Published: March 04, 2025

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: January 12, 2025

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).

Four-year outcomes with perioperative toripalimab plus chemotherapy in resectable stage III non-small cell lung cancer (NeoTAP01 study).

Journal: Journal of thoracic disease

Published: December 27, 2024

Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.

Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.

Journal: Frontiers in immunology

Published: April 24, 2024

Carbon dioxide gas-induced pneumothorax versus one-lung ventilation in minimally invasive esophagectomy: a multicenter propensity score matching cohort study.

Carbon dioxide gas-induced pneumothorax versus one-lung ventilation in minimally invasive esophagectomy: a multicenter propensity score matching cohort study.

Journal: International journal of surgery (London, England)

Published: September 25, 2023

miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in "driver gene-negative" non-small cell lung cancer via activating the Wnt/β-catenin signaling.

miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in "driver gene-negative" non-small cell lung cancer via activating the Wnt/β-catenin signaling.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: July 21, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026